A detailed history of Wetherby Asset Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Wetherby Asset Management Inc holds 42,642 shares of BMY stock, worth $2.4 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
42,642
Previous 38,327 11.26%
Holding current value
$2.4 Million
Previous $1.59 Million 38.65%
% of portfolio
0.1%
Previous 0.08%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $171,132 - $223,301
4,315 Added 11.26%
42,642 $2.21 Million
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $519,667 - $684,153
-12,911 Reduced 25.2%
38,327 $1.59 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $300,450 - $340,652
-6,262 Reduced 10.89%
51,238 $2.78 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $384,397 - $458,692
-7,929 Reduced 12.12%
57,500 $2.95 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $143,393 - $160,336
-2,477 Reduced 3.65%
65,429 $3.8 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $109,899 - $122,026
-1,725 Reduced 2.48%
67,906 $4.34 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $317,773 - $360,427
-4,836 Reduced 6.49%
69,631 $4.83 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $229,613 - $271,894
3,353 Added 4.71%
74,467 $5.36 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $458 - $271,091
3,528 Added 5.22%
71,114 $5.06 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $266,878 - $293,926
3,675 Added 5.75%
67,586 $5.2 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $260,798 - $312,720
4,242 Added 7.11%
63,911 $4.67 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $141,422 - $164,865
-2,637 Reduced 4.23%
59,669 $3.72 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $2,425 - $2,841
-41 Reduced 0.07%
62,306 $3.69 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $168,952 - $183,989
2,729 Added 4.58%
62,347 $4.17 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $233,146 - $262,221
-3,929 Reduced 6.18%
59,618 $3.76 Million
Q4 2020

Feb 11, 2021

BUY
$57.74 - $65.43 $15,705 - $17,796
272 Added 0.43%
63,547 $3.94 Million
Q3 2020

Dec 16, 2020

SELL
$57.43 - $63.64 $197,444 - $218,794
-3,438 Reduced 5.15%
63,275 $3.82 Million
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $277,961 - $308,017
4,840 Added 7.82%
66,713 $4.02 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $144,889 - $169,389
2,643 Added 4.46%
61,873 $3.64 Million
Q1 2020

May 06, 2020

BUY
$46.4 - $67.43 $502,651 - $730,469
10,833 Added 22.38%
59,230 $3.3 Million
Q4 2019

Jan 28, 2020

BUY
$49.21 - $64.19 $113,429 - $147,957
2,305 Added 5.0%
48,397 $3.11 Million
Q3 2019

Oct 31, 2019

BUY
$42.77 - $50.71 $34,258 - $40,618
801 Added 1.77%
46,092 $2.34 Million
Q2 2019

Jul 25, 2019

BUY
$44.62 - $49.34 $33,955 - $37,547
761 Added 1.71%
45,291 $2.05 Million
Q1 2019

May 09, 2019

SELL
$45.12 - $53.8 $45,616 - $54,391
-1,011 Reduced 2.22%
44,530 $2.12 Million
Q4 2018

Jan 30, 2019

SELL
$48.76 - $63.23 $130,823 - $169,646
-2,683 Reduced 5.56%
45,541 $2.37 Million
Q3 2018

Nov 07, 2018

BUY
$55.19 - $62.25 $110,711 - $124,873
2,006 Added 4.34%
48,224 $2.99 Million
Q2 2018

Jul 24, 2018

SELL
$50.53 - $62.98 $260,077 - $324,158
-5,147 Reduced 10.02%
46,218 $2.56 Million
Q1 2018

May 04, 2018

BUY
$59.92 - $68.98 $67,469 - $77,671
1,126 Added 2.24%
51,365 $3.25 Million
Q4 2017

Feb 09, 2018

BUY
$59.94 - $65.35 $13,846 - $15,095
231 Added 0.46%
50,239 $3.08 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $2.76 Million - $3.19 Million
50,008
50,008 $3.19 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Wetherby Asset Management Inc Portfolio

Follow Wetherby Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.